Modified Live PRRSV Vaccine Efficacy Prediction Using Immune Correlates
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current PRRSV vaccines face challenges in providing broad cross-reactivity against the diverse strains of PRRSV prevalent in the swine industry, necessitating a solution that induces heterologous immunogenicity to assess and predict vaccine efficacy effectively.
Innovation Solution
A method involving administration of a modified live PRRSV vaccine, followed by challenge with a known strain, measuring immune correlates such as CD4 T-cell response, neutralizing antibodies, and IFN-γ levels, to assess and predict vaccine efficacy against PRRSV strains.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Adaptability or versatility
If a PRRSV vaccine is designed to provide broad cross-reactivity against diverse strains, then vaccine efficacy against multiple strains is improved, but the complexity of evaluating and predicting efficacy increases
Solution Approach 1:
The patent segments the evaluation process into distinct components: measuring specific immune correlates (neutralizing antibodies, T-cell responses, cytokine production) separately from clinical outcome assessment. This allows systematic evaluation of vaccine efficacy against multiple strains through standardized immunological parameters rather than requiring complex integrated testing for each strain combination.
Solution Approach 2:
The patent introduces immune correlates of protection (neutralizing antibodies, T-cell responses, cytokine levels) as intermediary markers that mediate between vaccine administration and clinical efficacy. These intermediaries provide measurable, standardized endpoints that simplify the evaluation process while maintaining predictive value for actual vaccine performance against diverse PRRSV strains.
2Measurement precision
If multiple immune parameters are measured to assess vaccine efficacy, then prediction accuracy is improved, but the time required for assessment increases
Solution Approach 1:
The patent identifies and measures immune correlates of protection (neutralizing antibodies, T-cell responses, cytokine levels) at specific timepoints during the immune response trajectory. By capturing these parameters at critical stages (e.g., peak antibody response, T-cell activation phase), the assessment achieves high prediction accuracy without requiring continuous or prolonged monitoring of all parameters.
Solution Approach 2:
The patent focuses measurement on specific local immune parameters most predictive of protection (neutralizing antibodies for humoral response, T-cell responses and cytokine production for cellular response) rather than measuring all possible immune parameters uniformly. This targeted approach maintains high prediction accuracy while reducing overall assessment time and complexity.
Data Source
AI summary
Methods are provided for eliciting heterologous immunogenicity against heterologous porcine reproductive and respiratory syndrome virus (PRRSV) strains to allow assessment of innate immunity and adaptive immunity. In other aspects are provided methods for determining the efficacy of a vaccine against PRRSV. In still other aspects are provided methods for predicting the efficacy of a vaccine against PRRSV in pigs suspected of having an infection with PRRSV.